Chimeric antigen receptor (CAR) T cells have been successfully used for hematological malignancies, especially for relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. Patients who have undergone conventional chemo-immunotherapy and have relapsed can achieve complete remission for several months with the infusion of CAR T-cells. However, side effects and short duration of response are still major barriers to further CAR T-cell therapy. To improve the efficacy, multiple targets, the discovery of new target antigens, and CAR T-cell optimization have been extensively studied. Nevertheless, the fact that the determination of the efficacy of CAR T-cell therapy is inseparable from the discussion of clinical applicat...
The latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy contin...
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable response rates and revolution...
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinemen...
The stunning benefits of chimeric antigen receptor T (CAR-T) cell therapy in treatment of relapsed a...
Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treati...
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymp...
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable response rates and revolution...
Abstract. Cellular therapies have revolutionized the treatment of hematological malignancies since t...
Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with...
Over the last decade, the emergence of several novel therapeutic approaches has changed the therapeu...
Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with...
Chimeric antigen receptor (CAR) T-cell therapy is transforming the landscape for treatment of B-line...
Chimeric antigen receptor (CAR) T-cell therapy is transforming the landscape for treatment of B-line...
The development of chimeric antigen receptor T cells (CAR-T cells) has marked a new era in cancer im...
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of pa...
The latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy contin...
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable response rates and revolution...
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinemen...
The stunning benefits of chimeric antigen receptor T (CAR-T) cell therapy in treatment of relapsed a...
Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treati...
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymp...
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable response rates and revolution...
Abstract. Cellular therapies have revolutionized the treatment of hematological malignancies since t...
Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with...
Over the last decade, the emergence of several novel therapeutic approaches has changed the therapeu...
Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes for patients with...
Chimeric antigen receptor (CAR) T-cell therapy is transforming the landscape for treatment of B-line...
Chimeric antigen receptor (CAR) T-cell therapy is transforming the landscape for treatment of B-line...
The development of chimeric antigen receptor T cells (CAR-T cells) has marked a new era in cancer im...
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of pa...
The latest clinical and real-world evidence of chimeric antigen receptor (CAR) T-cell therapy contin...
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable response rates and revolution...
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinemen...